Research programme: erythropoietin receptor agonists - Viking Therapeutics

Drug Profile

Research programme: erythropoietin receptor agonists - Viking Therapeutics

Alternative Names: EPO receptor agonists - Viking Therapeutics; LG 5640

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurogen Corporation
  • Developer Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 21 Mar 2017 Viking Therapeutics has patent protection and pending patent applications for erythropoietin receptor agonists in USA, Australia, Canada, China, Europe, India, Japan and Korea
  • 06 Feb 2015 Preclinical development is ongoing in USA
  • 22 May 2014 Erythropoietin receptor agonists research programme licensed to Viking Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top